Therapeutic Strategies With Selective CDK4/6 Inhibitors: An Oncologist’s Guide to Safe Inhibition of Uncontrolled Cellular Proliferation in Solid Tumors

Download All
Review recent developments with selective CDK4/6 inhibitors in the care of patients with various cancers in this text module, on-demand Webcast, and accompanying slideset developed by Richard Finn, MD; Geoffrey Shapiro, MD, PhD; and Gary K. Schwartz, MD.
Richard Finn, MD
Gary K. Schwartz, MD
Geoffrey Shapiro, MD, PhD

Selective CDK4/6 Inhibitors in Cancer: Moving Beyond Breast Cancer

Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.

Richard Finn, MD Gary K. Schwartz, MD Geoffrey Shapiro, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 14, 2017 Expired: No longer available for credit

The first of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review critical data on the mechanisms of CDK4/6 inhibition and its clinical effects in various cancer types.

Released: June 8, 2017

The second of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review critical studies on the clinical and preclinical characteristics of CDK4/6 inhibitors in multiple tumor types.

Released: June 8, 2017

The third of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review key data on combining CDK4/6 inhibitors with hormone therapy, PI3K inhibitors, and others in multiple cancers.

Released: June 8, 2017

In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.

Released: April 14, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings